US Patent

US11479557 — Inhibitors of the menin-MLL interaction

Method of Use · Assigned to Vitae Pharmaceuticals LLC · Expires 2037-06-08 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects inhibitors of the menin-MLL interaction, which are used in the treatment of cancer and other diseases.

USPTO Abstract

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4327`	—	revumenib-citrate
`U-4327`	—	revumenib-citrate
`U-4327`	—	revumenib-citrate

Patent Metadata

Patent number: US11479557
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-08
Drug substance claim: No
Drug product claim: Yes
Assignee: Vitae Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.